{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:52:04Z","timestamp":1777690324792,"version":"3.51.4"},"reference-count":7,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2018,3,11]]},"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>Sodium valproate remains the best drug for idiopathic generalised epilepsy. For men with the latter diagnosis, this is the drug of choice. Sodium valproate has an unacceptably high level of major fetal malformation and also causes learning disabilities in many children exposed to the drug in utero. Women of reproductive age should not normally be offered this drug. There are many women with refractory epilepsy who would benefit from this drug and who are not planning pregnancy. Individualised epilepsy care is the gold standard, not blanket bans on drug choice based on gender.<\/jats:p>","DOI":"10.1136\/practneurol-2018-001931","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T19:30:12Z","timestamp":1524511812000},"page":"222-223","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Valproate and epilepsy: for women as well as men"],"prefix":"10.1136","volume":"18","author":[{"given":"Charlotte","family":"Lawthom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"key":"2025090409373784000_18.3.222.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.51204.x"},{"key":"2025090409373784000_18.3.222.2","unstructured":"Nice. Epilepsies: diagnosis and management Clinical guideline [CG137], 2012."},{"key":"2025090409373784000_18.3.222.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306318"},{"key":"2025090409373784000_18.3.222.4","unstructured":"Toolkit on the risks of valproate medicines in female patients. Medicines & Healthcare products Regulatory Agency. https:\/\/www.gov.uk\/government\/publications\/toolkit-on-the-risks-of-valproate-medicines-in-female-patients"},{"key":"2025090409373784000_18.3.222.5","unstructured":"Office of National Statistics. Statistical bulletin: conceptions in England and Wales: 2015 Annual statistics on conceptions covering conception counts and rates, by age group including women under 18."},{"key":"2025090409373784000_18.3.222.6","unstructured":"U.S. Census Bureau. Population. https:\/\/census.gov\/topics\/population.html"},{"key":"2025090409373784000_18.3.222.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60461-9"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2018-001931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T16:37:42Z","timestamp":1757003862000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2018-001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":7,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,5,18]]},"published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1136\/practneurol-2018-001931"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2018-001931","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]}}}